Minimally Invasive Groin Dissection for Melanoma (SAFE-MILND)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Mayo Clinic
Sponsor:
Information provided by (Responsible Party):
James W. Jakub, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01500304
First received: December 22, 2011
Last updated: October 3, 2014
Last verified: October 2014
  Purpose

The purpose of this this study is to determine if a structured educational training program is successful in teaching surgeons a new operative technique. It will then be determined if this new operative technique is safe.


Condition Intervention Phase
Melanoma
Procedure: Minimally invasive inguinal lymph node dissection
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Proficiency score per surgery [ Time Frame: Approximately 90 days following surgical procedure ] [ Designated as safety issue: No ]
    The proficiency score is a function of the lymph nodes pathologically identified, the amount of blood transfused and the operative time. The range is 0 to 3, with higher proficiency in performing the procedure being 3.


Secondary Outcome Measures:
  • Morbidity and percentage of patients converted to open surgical procedure [ Time Frame: Approximately 90 days following surgical procedure ] [ Designated as safety issue: No ]
    Perioperative morbidity will be prospectively collected and reported.Percentage of participants that require conversion from MILND to open procedure (standard of care). Conversion to the open procedure is required if the operation is not progressing, an adequate oncologic procedure cannot be completed or if bleeding is encountered that cannot be safety controlled videoscopically.


Estimated Enrollment: 100
Study Start Date: June 2012
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Minimally invasive surgery
Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
Procedure: Minimally invasive inguinal lymph node dissection

Detailed Description:

This study is a multi-center, Phase 1 clinical trial to determine the safety and feasibility of minimally invasive inguinal lymph node dissection for patients with melanoma. Licensed surgeons who have undergone special training, including a course at the Mayo Clinic Rochester in minimally invasive lymph node dissection (MILND) will perform the new procedure at their home institutions. The study will characterize the learning curve of MILND in the clinical setting, and evaluate the safety of the new operative technique.

The hypotheses for this study are: 1) minimally invasive groin dissection is a safe procedure. 2) a structured educational training program is a feasible and effective method to train practicing surgeons in this novel procedure and 3) pre-course generic laparoscopic technical skills correlate with minimally invasive superficial groin dissection performance in a clinical setting, including operative oncologic standards and safety metrics.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Malignant melanoma present in an inguinal nodal basin requiring superficial inguinal lymph node dissection.
  • Plan for superficial inguinal dissection alone or combined superficial inguinal and deep pelvic node dissection is acceptable.
  • Clinical or radiographic evidence of superficial inguinal lymph node disease or a prior positive single lymph node biopsy of the superficial inguinal basin as an indication for superficial inguinal lymph node disease is acceptable.
  • Patients must be Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and be healthy enough to undergo a general anesthetic (no epidural or spinal anesthetics).
  • Female patients of child bearing age must have a negative pregnancy test, be surgically sterile or post-menopausal greater than 1 year.
  • Patients must be able to return to surgical facility for 30 and/or 90 day (+/- 20 days) for follow-up appointment.

Exclusion Criteria:

  • Prior ipsilateral superficial inguinal lymph node dissection
  • Invasion or ulceration of inguinal nodal disease into the overlying skin
  • Prior radiation therapy to the same regional nodal basin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01500304

Contacts
Contact: James Jakub, MD 507-284-0362 jakub.james@mayo.edu

Locations
United States, Arizona
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Nabil Wasif, MD    480-342-2849      
Sub-Investigator: Nabil Wasif         
United States, California
John Wayne Cancer Institute Recruiting
Santa Monica, California, United States, 90404
Contact: Kelly P. Garver    310-582-7456    garverk@jwci.org   
Principal Investigator: Mark Faries, M.D.         
United States, Florida
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224
Contact: Mauricia Buchanan, R.N.    904-953-9455    buchanan.mauricia@mayo.edu   
Sub-Investigator: Sanjay Bagaria, M.D.         
H. Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
Contact: Erica Royster    813-745-4279    Erica.Royster@moffitt.org   
Principal Investigator: Amod Sarnaik         
United States, Illinois
Northwestern Memorial Hospital Recruiting
Chicago, Illinois, United States, 60611
Contact: Brandy Jackson-Davis    312-695-1357    brandy.jackson-davis@northwestern.edu   
Principal Investigator: Karl Bilimoria, M.D.         
Principal Investigator: Jeff Wayne, M.D.         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Charlotte E. Ariyan, M.D.    212-639-6280      
Contact: Mary S. Brady, M.D.    212-639-8347      
Principal Investigator: Charlotte E. Ariyan, M.D.         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Kristen Linney    919-684-8239    k.linney@duke.edu   
Principal Investigator: Douglas Tyler, M.D.         
United States, Ohio
MetroHealth Medical Center Recruiting
Cleveland, Ohio, United States, 44109
Contact: Mary Workman    216-778-8433    mworkman@metrohealth.org   
Principal Investigator: Bruce Averbook         
The Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Amber Rheinscheild    614-293-3806    amber.rheinscheld@osumc.edu   
Principal Investigator: Alicia Terando, M.D.         
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Jeffrey Farma, M.D.    215-728-2419      
Contact: Jeanne Focht-Bhasin, R.N.    215-728-5528    Jeanne.Focht-Bhasin@fccc.edu   
Principal Investigator: Jeffrey Farma, M.D.         
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Contact: Nicky L. Kurtzweil    608-262-9383    kurtzweil@surgery.wisc.edu   
Principal Investigator: Heather B. Neuman, M.D.         
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: James Jakub, MD Mayo Clinic
  More Information

Additional Information:
Publications:
Responsible Party: James W. Jakub, Breast and Melanoma Surgery Section Head, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01500304     History of Changes
Other Study ID Numbers: 10-007790
Study First Received: December 22, 2011
Last Updated: October 3, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Melanoma
Lymph Nodes
Lymph Node Dissection
Minimally invasive

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on October 22, 2014